EMBARGOED FOR RELEASE: 3 P.M. (CT), MONDAY, JANUARY 20, 2014
Media Advisory: To contact author Alberto Ascherio, M.D., Dr.P.H., call Karen Feldscher at 617-432-8439 or email email@example.com.
JAMA Neurology Study Highlights
Vitamin D status appears to be associated with reduced disease activity in patients with multiple sclerosis (MS) and a slower rate of disease progression, according to a study by Alberto Ascherio, M.D., Dr.P.H., of the Harvard School of Public Health, Boston, and colleagues.
MS is a common cause of neurological disability and vitamin D status may be related to the disease process, according to the study background.
Researchers examined whether blood concentration of 25-hydroxyvitamin D (25[OH]D), a marker of vitamin D status, was associated with MS disease activity and progression in patients with a first episode suggestive of MS.
Blood 25[OH]D levels were measured as part of a randomized trial originally designed to study patients given interferon beta-1b treatment. A total of 465 patients (of the 468 enrolled) had at least one 25[OH]D measurement. Patients were followed for up to five years with magnetic resonance imaging.
Increases of 50-nmol/L in average blood 25[OH]D levels within the first 12 months appeared to be associated with a 57 percent lower risk of new active brain lesions, 57 percent lower risk of relapse, 25 percent lower yearly increase in T2 lesion volume and 0.41 percent lower yearly loss in brain volume from months 12 to 60.
“Among patients with MS mainly treated with interferon beta-1b, low 25[OH]D levels early in the disease course are a strong risk factor for long-term MS activity and progression,” the study concludes.
(JAMA Neurol. Published online January 20, 2014. doi:10.1001/.jamaneurol.2013.5993. Available pre-embargo to the media at http://media.jamanetwork.com.)
Editor’s Note: Authors made conflict of interest disclosures. This study was supported by the National Institute of Neurological Diseases and Stroke and the National Multiple Sclerosis Society. The BENEFIT study was sponsored by Bayer. Please see the articles for additional information, including other authors, author contributions and affiliations, financial disclosures, funding and support, etc.
# # #
For more information, contact JAMA Network Media Relations at 312-464-JAMA (5262) or email firstname.lastname@example.org.